Tags

Type your tag names separated by a space and hit enter

Efficacy comparison of medications approved for chronic weight management.
Obesity (Silver Spring). 2015 Apr; 23 Suppl 1:S4-7.O

Abstract

For the first time, patients who are obese are able to benefit from 5 different FDA approved pharmacologic agents for chronic weight management. Although weight loss from all of these medications was limited to 5% to 10% of total body weight loss in the Phase III clinical trials, patients are capable of losing more weight when a cumulative approach of diet, exercise, and multiple medications are used. A pilot study of adding phentermine to lorcaserin yielded double the weight loss than lorcaserin alone. A higher percentage of total body weight is lost with use of combination phentermine/topiramate compared to orlistat, lorcaserin, and bupropion/naltrexone but there are more contraindications to its use and potential cardiovascular adverse effects due to adrenergic agonism. Lorcaserin and bupropion/naltrexone yielded similar weight loss but carry different adverse effect profiles and interactions with other psychiatric medications may preclude use of one over the other. When choosing a medication for obesity, several factors need to be considered, such as comorbidities, medication interactions, and risk of potential adverse effects.

Authors+Show Affiliations

Weill Cornell Medical College, Department of Endocrinology, Diabetes, & Metabolism, Comprehensive Weight Control Center, New York, New York, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25900871

Citation

Kumar, Rekha B., and Louis J. Aronne. "Efficacy Comparison of Medications Approved for Chronic Weight Management." Obesity (Silver Spring, Md.), vol. 23 Suppl 1, 2015, pp. S4-7.
Kumar RB, Aronne LJ. Efficacy comparison of medications approved for chronic weight management. Obesity (Silver Spring). 2015;23 Suppl 1:S4-7.
Kumar, R. B., & Aronne, L. J. (2015). Efficacy comparison of medications approved for chronic weight management. Obesity (Silver Spring, Md.), 23 Suppl 1, S4-7. https://doi.org/10.1002/oby.21093
Kumar RB, Aronne LJ. Efficacy Comparison of Medications Approved for Chronic Weight Management. Obesity (Silver Spring). 2015;23 Suppl 1:S4-7. PubMed PMID: 25900871.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy comparison of medications approved for chronic weight management. AU - Kumar,Rekha B, AU - Aronne,Louis J, PY - 2015/4/23/entrez PY - 2015/4/23/pubmed PY - 2015/9/26/medline SP - S4 EP - 7 JF - Obesity (Silver Spring, Md.) JO - Obesity (Silver Spring) VL - 23 Suppl 1 N2 - For the first time, patients who are obese are able to benefit from 5 different FDA approved pharmacologic agents for chronic weight management. Although weight loss from all of these medications was limited to 5% to 10% of total body weight loss in the Phase III clinical trials, patients are capable of losing more weight when a cumulative approach of diet, exercise, and multiple medications are used. A pilot study of adding phentermine to lorcaserin yielded double the weight loss than lorcaserin alone. A higher percentage of total body weight is lost with use of combination phentermine/topiramate compared to orlistat, lorcaserin, and bupropion/naltrexone but there are more contraindications to its use and potential cardiovascular adverse effects due to adrenergic agonism. Lorcaserin and bupropion/naltrexone yielded similar weight loss but carry different adverse effect profiles and interactions with other psychiatric medications may preclude use of one over the other. When choosing a medication for obesity, several factors need to be considered, such as comorbidities, medication interactions, and risk of potential adverse effects. SN - 1930-739X UR - https://www.unboundmedicine.com/medline/citation/25900871/Efficacy_comparison_of_medications_approved_for_chronic_weight_management_ L2 - https://doi.org/10.1002/oby.21093 DB - PRIME DP - Unbound Medicine ER -